Cancer genetics > Press reviews

Illumina is to conduct genotyping of prostate cancer patients and controls in order to help researchers funded by Cancer Research UK to understand the genetic causes of the disease.
From the work, it is hoped that it will be possible in the future to design and validate biomarkers associated with prostate cancer susceptibility and disease progression, as well as to facilitate development of improved therapeutic approaches.
Under the terms of the agreement, valued at nearly $7 million, (...)

Illumina has been awarded a genotyping services contract by SAIC-Frederick, under prime contract to the National Cancer Institute, to perform whole-genome scans on over 2,500 prostrate case and control samples provided by the Institute.
The genotyping supports a study known as the Cancer Genetic Markers of Susceptibility (CGEMS), a National Cancer Institute (NCI) strategic initiative.
The CGEMS initiative is designed to map susceptibility in prostrate and breast cancers, with the aim of (...)